Cristin-resultat-ID: 1911705
Sist endret: 6. januar 2022, 10:02
NVI-rapporteringsår: 2021
Resultat
Vitenskapelig artikkel
2021

Interlaboratory comparison investigations (ICI) and external quality assurance schemes (EQUAS) for cadmium in urine and blood: Results from the HBM4EU project

Bidragsytere:
  • Stefanie Nübler
  • Marta Esteban López
  • Argelia Castaño
  • Hans Mol
  • Moritz Schäfer
  • Karin Haji-Abbas-Zarrabi
  • mfl.

Tidsskrift

International Journal of Hygiene and Environmental Health
ISSN 1438-4639
e-ISSN 1618-131X
NVI-nivå 2

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2021
Publisert online: 2021
Volum: 234
Artikkelnummer: 113711
Open Access

Importkilder

Scopus-ID: 2-s2.0-85103137710

Beskrivelse Beskrivelse

Tittel

Interlaboratory comparison investigations (ICI) and external quality assurance schemes (EQUAS) for cadmium in urine and blood: Results from the HBM4EU project

Sammendrag

Human biomonitoring (HBM) of cadmium is essential to assess and prevent toxic exposure. Generally, low cadmium levels in urine and blood of the general population place particularly high demands on quality assurance and control measures (QA/QC) for cadmium determination. One of the aims of the HBM4EU project is to harmonize and advance HBM in Europe. Cadmium is one of the chemicals selected as a priority substance for HBM implementation in the 30 European countries under HBM4EU. For this purpose, analytical comparability and accuracy of the analytical laboratories of participating countries was investigated in a QA/QC programme comprising interlaboratory comparison investigations (ICI) and external quality assurance schemes (EQUAS). This paper presents the evaluation process and discusses the results of four ICI/EQUAS rounds for the deter-mination of cadmium in urine and blood. The majority of the 43 participating laboratories achieved satisfactory results, although low limits of quantification were required to quantify Cd concentrations at general population exposure levels. The relative standard deviation of the participants’ results obtained from all ICI and EQUAS runs ranged from 8 to 36% for cadmium in urine and 8–28% for cadmium in blood. Applying inductively-coupled plasma mass spectrometry (ICP-MS), using an internal standard, and eliminating molybdenum oxide in-terferences was favourable for the accurate determination of cadmium in urine and blood. Furthermore, the analysis of cadmium in urine was found to have a critical point at approximately 0.05 μg/l, below which vari-ability increased and laboratory proficiency decreased. This QA/QC programme succeeded in establishing a network of laboratories with high analytical comparability and accuracy for the analysis of cadmium across 20 European countries.

Bidragsytere

Stefanie Nübler

  • Tilknyttet:
    Forfatter
    ved Friedrich-Alexander-Universität Erlangen-Nürnberg

Marta Esteban López

  • Tilknyttet:
    Forfatter
    ved Instituto de Salud Carlos III

Argelia Castaño

  • Tilknyttet:
    Forfatter
    ved Instituto de Salud Carlos III

Hans Mol

  • Tilknyttet:
    Forfatter
    ved Wageningen University & Research

Moritz Schäfer

  • Tilknyttet:
    Forfatter
    ved Friedrich-Alexander-Universität Erlangen-Nürnberg
1 - 5 av 15 | Neste | Siste »